Quantcast
Home > Quotes > ODT

Odonate Therapeutics, Inc. Common Stock (ODT) Quote & Summary Data

ODT 
$22.57
*  
0.01
0.04%
Get ODT Alerts
*Delayed - data as of Apr. 24, 2019 12:54 ET  -  Find a broker to begin trading ODT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ODT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 22.12 / $ 22.60
1 Year Target
31
Today's High / Low
$ 23.08 / $ 22.13
Share Volume
7,851
50 Day Avg. Daily Volume
58,993
Previous Close
$ 22.56
52 Week High / Low
$ 28.57 / $ 11.54
Market Cap
603,807,739
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.63
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.55

Intraday Chart

Shares Traded

Share Volume:
7,851
50 Day Avg. Daily Volume:
58,993

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.63

Trading Range

The current last sale of $22.57 is 95.58% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 23.08 $ 28.57
 Low: $ 22.13 $ 11.54

Company Description (as filed with the SEC)

We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several pharmacologic properties that make it unique among taxanes, including: oral administration with a low pill burden; a long (~8-day) terminal plasma half-life ("t1/2") in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and significant activity against chemotherapy-resistant tumors. In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies.  ... More ...  



Risk Grade

Where does ODT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 22.67
Open Date:
Apr. 24, 2019
Close Price:
$ 22.56
Close Date:
Apr. 23, 2019


Consensus Recommendation

Analyst Info